Pharmacologic treatment of chronic obstructive pulmonary disease: Past, present, and future

Pharmacotherapy

Volumn 23, Issue 10 II, 2003, Pages 1300-1315

  Faulkner, Michele A ^a   Hilleman, Daniel E ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FORMOTEROL; IPRATROPIUM BROMIDE; PNEUMOCOCCUS VACCINE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HUMAN; IMMUNIZATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING CESSATION; SPIROMETRY; TACHYCARDIA; TREMOR;

ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY, ACTIVE; OXYGEN; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SMOKING CESSATION;

EID: 0141754104     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.12.1300.32699     Document Type: Review

References (102)

1. Barnes PJ. New treatments for COPD. Nat Rev Drug Discov 2002;1:437-46.
2. National Heart, Lung, and Blood Institute/World Health Organization. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. National Heart, Lung, and Blood Institute/World Health Organization workshop report. Available from www.goldcopd.com. Accessed December 23, 2002.
3. Antó JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001;17:982-94.
4. Donohue JF. COPD: An update on treatment. Pulm Perspect 2001;18:7-9.
5. Heffner JE. Chronic obstructive pulmonary disease: on an exponential curve of progress. Resp Care 2002;47:586-607.
6. Calverley PMA. COPD: early detection and intervention. Chest 2000;117(suppl 2):S365-71.
7. Barnes PJ. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:S72-9.
8. Piqueras MG, Cosio MG. Disease of the airways in chronic obstructive pulmonary disease. Eur Respir J 2001;18(suppl 34):S41-9.
9. Barnes PJ. Mechanisms in COPD: differences from asthma. Chest 2000;117:S10-14.
10. Saetta M, Turato G. Airway pathology in asthma. Eur Respir J 2001;18(suppl 34):S18-23.
11. Leckie MJ, Bryan SA, Hansel TT, Barnes PJ. Novel therapy for COPD. Exp Opin Invest Drugs 2000;9:3-23.
12. Thompson PB, Daughton D, Robbins GA, et al. Intramural airway inflammation in chronic bronchitis: characterization and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527-37.
13. Rennard SI. Overview and causes of COPD. Postgrad Med 2002;111:28-38.
14. Petty TL. COPD in perspective. Chest 2002;121:S116-20.
15. Faulkner MA, Hilleman DE. The economic impact of chronic obstructive pulmonary disease. Exp Opin Pharmacother 2002;3:219-28.
16. Saint S, Flaherty KR, Abrahamse P, Martinez FJ, Fendrick AM. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy. Clin Ther 2001;23:499-512.
17. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease (Cochrane review). In: The Cochrane library, 2, 2003. Oxford, UK: Update Software.
18. Rogers DF. Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opin Investig Drugs 2002;11:15-35.
19. British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985;40:832-5.
20. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000;22:209-21.
21. 1 decline and chronic obstructive pulmonary disease morbidity: Copenhagen City heart study group. Am J Respir Crit Care Med 1996;153:1530-5.
22. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995;8:1333-8.
23. Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease (Cochrane review). The Cochrane library, 2, 2003. Oxford, UK: Update Software.
24. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152(5 Pt 2):S77-121.
25. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 1993; 328:1017-22.
26. Ferguson GT. Update on pharmacologic therapy for chronic obstructive pulmonary disease. Clin Chest Med 2000;21:723-38.
27. Hvizdos KM, Goa KL. Tiotropium bromide. Drugs 2002;62:1195-203.
28. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999;159:156-60.
29. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994;105:1411-19.
30. 2-agonists on clinical outcomes in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2002;110:S298-303.
31. Calverley PMA. Modern treatment of chronic obstructive pulmonary disease. Eur Respir J 2001;18(suppl 34):S60-6.
32. Chapman KR. Clinical implications of anticholinergic bronchodilator therapy in COPD. Res Clin Forums 1991;13:43-50.
33. Dahl R, Greefhorst LAPM, Nowak D, et al, on behalf of the Formoterol in Chronic Obstructive Pulmonary Disease 1 Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84.
34. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive disease: a dose-response study. Respir Med 1995;89:357-62.
35. Friedman M, Dello Cioppa D, Kottakis J. Formoterol therapy for chronic obstructive pulmonary disease: a review of the literature. Pharmacotherapy 2002;22:1129-39.
36. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087-92.
37. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997;112:336-40.
38. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-65.
39. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69.
40. D'Urzo AD, De Salvo MC, Ramirez A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium. Chest 2001;119:1347-56.
41. Howells CHL, Tyler LE. Prophylactic use of influenza vaccine in patients with chronic bronchitis. Lancet 1961;30:1428-32.
42. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437-42.
43. Broome CV. Efficacy of pneumococcal polysaccharide vaccine. Rev Infect Dis 1981;3(suppl):S82-96.
44. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients: results of a Veterans Administration cooperative study. N Engl J Med 1986;315:1318-27.
45. Davies AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic pulmonary disease: a pilot study Chest 1987;92:204-12.
46. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Can Med Assoc J 1987;136:361-5.
47. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-8):1-24.
48. Thompson GH, Hunter DA. Nicotine replacement therapy. Ann Pharmacother 1998;32:1067-75.
49. Sutherland G. Current approaches to the management of smoking cessation. Drugs 2002;62(suppl 2):53-61.
50. West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology 2001;153:225-30.
51. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadows A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999;159:2033-8.
52. National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. National Institute for Clinical Excellence technology appraisal guidance no. 39. April 2002. Available from http://www.nice.org.uk. Accessed February 26, 2003.
53. Britton J, Jarvis MJ. Bupropion: a new treatment for smokers. Nicotine replacement treatment should also be available on the NHS. BMJ 2000;321:65-6.
54. Covey LS, Sullivan MA, Johnston JA, Glassman AH, Robinson MD, Adams DP. Advances in non-nicotine pharmacotherapy for smoking cessation. Drugs 2000; 59:17-31.
55. Baldesarrini RJ. Risk rates for depression. Arch Gen Psychiatry 1984;41:103-6.
56. Hall SM, Munoz RF, Reus VI. Depression and smoking treatment: a clinical trial of an affect regulation treatment. NIDA Res Monogr 1992;119:326.
57. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-9.
58. Coleman T. Smoking cessation: integrating recent advances into clinical practice. Thorax 2001;56:579-82.
59. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine and ibogaine. J Pharmacol Exp Ther 1999;288:88-92.
60. Henningfield JE, Fant RV, Gitchell J, et al. Tobacco dependence: global public health potential for new medications development and indications. Ann NY Acad Sci 2000;909:247-56.
61. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation (Cochrane review). The Cochrane library, 2, 2003. Oxford, UK: Update Software.
62. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.
63. Bohadana A, Nilsson F, Rasmussen T, et al. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2000;160:3128-34.
64. Hayford KE, Patten CA, Rummans TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999;174:173-8.
65. Benowitz NL, Wilson Peng M. Non-nicotine pharmacotherapy for smoking cessation: mechanisms and prospects. CNS Drugs 2000;13:265-85.
66. Kotlyar M, Golding M, Hatsukami DK, Jamerson BD. Effect of nonnicotine pharmacotherapy on smoking behavior. Pharmacotherapy 2001;21:1530-48.
67. da Costa CL, Younes RN, Lourenço MTC. Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 2002;122:403-8.
68. Hall SM, Reus VI, Muñoz RF, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998;55:683-93.
69. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation (Cochrane review). The Cochrane library, 2, 2003. Oxford, UK: Update Software.
70. Glassman AH, Stetner F, Walsh T, et al. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 1988;259:2863-6.
71. Glassman AH, Covey LS, Dalack GW, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993;54:670-9.
72. Gourlay SG, Forbes A, Marriner T, et al. A placebo-controlled study of three doses for smoking cessation. Clin Pharm Ther 1994;55:64-9.
73. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy? Drugs 1995;50:197-207.
74. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8.
75. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92:753-8.
76. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340:1941-7.
77. Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999;354:456-60.
78. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
79. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
80. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
81. Pauwels RA, Lofdahl CG, Laitnen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999;340:1948-53.
82. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
83. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:580-4.
84. Whittaker AJM, Spiro SG. Inhaled steroid therapy in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2000;6:104-9.
85. Eiser N, Angus K, McHale S. The role of domiciliary nebulizers in managing patients with severe COPD. Respir Med 2001;95:265-74.
86. Ikeda A, Nishimura K, Koyama H, et al. Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease. Respiration 1999;66:119-23.
87. Maesen FPV, Smeets JJ, Sledsens TJM, Waki FDM, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1506-13.
88. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55.
89. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16.
90. van Noord JA, Bantje ThA, Eland ME, Korduckio L, Cornelissen PJ, on behalf of the Dutch Tiotropium Study Group. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000;55:289-94.
91. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
92. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-42.
93. Pettersen CA, Adler KB. Airways inflammation and COPD: epithelial-neutrophil interactions. Chest 2002;121:S142-50.
94. 4 antagonist LY293111 on allergen-induced responses in asthma. Thorax 1996;51:1178-84.
95. Kilfeather S. 5-Lipoxygenase inhibitors for the treatment of COPD. Chest 2002;121:S197-200.
96. White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273:10095-8.
97. Barnes PJ. Cytokine modulators as novel therapies for airway disease. Eur Respir J 2001;18(suppl 34):S67-77.
98. Cawston T, Carrere S, Catterall J, et al. Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronic obstructive pulmonary disease. Novartis Found Symp 2001;234:205-18.
99. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 2002;121:S192-6.
100. Compton CH, Gubb J, Cedar E, et al. The efficacy of Ariflo (SB207499), a second generation oral PDE4 inhibitor, in patients with COPD [abstr]. Am J Resp Crit Care Med 1999;195(suppl):A806.
101. Hautamaki RD, Kobayashi DK, Senior RM, et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277:2002-4.
102. Barnes PJ, Belvisi MG, Rogers DF. Modulation of neurogenic inflammation: novel approaches to inflammatory diseases. Trends Pharmacol Sci 1990;11:185-9.